Consider Trelegy a Last-Line Option for COPD

Trelegy Ellipta (TREL-eh-gee) will be the first "three-in-one" inhaler for COPD.

It contains the long-acting muscarinic antagonist (LAMA) umeclidinium...the long-acting beta-agonist (LABA) vilanterol...and the inhaled corticosteroid (ICS) fluticasone furoate.

Trelegy is a dry-powder inhaler given as a single puff once daily.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote